Table 1.
Age-standardized cancer incidence rates (ASIR) and rate ratios by SEER and IARC/IACR multiple primary coding rules and age at diagnosis of leading cancers (SEER: 2005–2009
| Site | Sex | ASIR | ASIR ratios (SEER: IARC/IACR) | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| SEER | IARC/IACR | All ages | 0–19 | 20–44 | 45–64 | 65+ | ||
| All sites | Both | 475.3 (474.1, 476.4) | 461.1 | 1.03* | 1.00 | 1.02* | 1.02* | 1.03* |
| Oral cavity and pharynx | Both | 10.9 (10.7, 11.0) | 10.5 | 1.03* | 1.00 | 1.01 | 1.02 | 1.05* |
| Esophagus | Both | 4.7 (4.6, 4.8) | 4.6 | 1.00 | 1.00 | 1.01 | 1.00 | 1.00 |
| Stomach | Both | 7.4 (7.3, 7.5) | 7.4 | 1.01 | 1.00 | 1.00 | 1.01 | 1.01 |
| Colon excluding rectum | Both | 33.0 (32.7, 33.3) | 31.5 | 1.04* | 1.04 | 1.02 | 1.03* | 1.05* |
| Rectum and rectosigmoid junction | Both | 12.8 (12.7, 13.0) | 12.7 | 1.01 | 1.00 | 1.01 | 1.01 | 1.01 |
| Liver and intrahepatic bile duct | Both | 7.5 (7.3, 7.6) | 7.4 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Pancreas | Both | 12.6 (12.4, 12.8) | 12.6 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Larynx | Both | 3.3 (3.2, 3.4) | 3.2 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Lung and bronchus | Both | 61.4 (61.9, 61.8) | 60.0 | 1.02* | 1.00 | 1.01 | 1.01 | 1.03* |
| Melanoma | Both | 22.5 (22.3, 22.7) | 20.8 | 1.09* | 1.00 | 1.04 | 1.08* | 1.13* |
| Breast | F | 127.9 (127.1, 128.7) | 117.1 | 1.07* | 1.00 | 1.04* | 1.06* | 1.10* |
| Cervix uteri | F | 6.8 (6.6, 7.0) | 6.8 | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Corpus uterine | F | 25.1 (24.8, 25.5) | 25.1 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Ovary | F | 13.0 (12.7, 13.2) | 12.9 | 1.00 | 1.00 | 1.01 | 1.00 | 1.00 |
| Prostate | M | 162.9 (161.9, 163.9) | 162.9 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Testis | M | 6.0 (5.8, 6.2) | 5.8 | 1.03 | 1.00 | 1.03 | 1.03 | 1.00 |
| Urinary bladder | Both | 21.5 (21.2, 21.7) | 20.3 | 1.06* | 1.00 | 1.02 | 1.03* | 1.06* |
| Kidney and renal pelvis | Both | 15.1 (14.9, 15.3) | 14.5 | 1.04* | 1.03 | 1.03 | 1.03* | 1.05* |
| Brain and other nervous system | Both | 6.6 (6.5, 6.8) | 6.6 | 1.01 | 1.01 | 1.02 | 1.01 | 1.00 |
| Thyroid | Both | 12.4 (12.3, 12.7) | 12.4 | 1.01 | 1.00 | 1.00 | 1.01 | 1.01 |
| Hodgkin lymphoma | Both | 3.0 (2.9, 3.1) | 2.8 | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Non-Hodgkin lymphoma | Both | 20.8 (20.5, 21.0) | 20.3 | 1.02* | 1.00 | 1.01 | 1.02 | 1.03* |
| Myeloma | Both | 6.2 (6.0, 6.3) | 6.1 | 1.02 | 1.00 | 1.01 | 1.01 | 1.02 |
| Leukemia | Both | 13.5 (13.3, 13.7) | 13.3 | 1.01 | 1.00 | 1.01 | 1.01 | 1.02 |
| Mesothelioma | Both | 1.0 (0.9, 1.0) | 1.0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Kaposi sarcoma | Both | 0.7 (0.6, 0.7) | 0.7 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
*
Rate differences between SEER MP and IARC/IACR MP data sets where the 5-year IARC/IACR rate estimate was not contained within the corresponding 95 % CIs from the SEER MP rate estimate